Patents by Inventor Kimberly Perkins

Kimberly Perkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS
    Publication number: 20220401556
    Abstract: Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that is a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA1P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.
    Type: Application
    Filed: August 22, 2022
    Publication date: December 22, 2022
    Inventors: David J. CHAPLIN, Kimberly PERKINS
  • Use of VDAS to enhance immunomodulating therapies against tumors
    Patent number: 11419934
    Abstract: Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA1P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: August 23, 2022
    Assignee: Oncotelic Therapeutics, Inc.
    Inventors: David J. Chaplin, Kimberly Perkins
  • USE OF VDAS TO ENHANCE IMMUNOMODULATING THERAPIES AGAINST TUMORS
    Publication number: 20190008956
    Abstract: Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA 1 P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.
    Type: Application
    Filed: August 17, 2016
    Publication date: January 10, 2019
    Applicant: MATEON THERAPEUTICS, INC.
    Inventors: David J. CHAPLIN, Kimberly PERKINS
  • Pulmonary administration of chemically modified insulin
    Publication number: 20050152848
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Application
    Filed: November 2, 2004
    Publication date: July 14, 2005
    Inventors: John Patton, Mei-Chang Kuo, J. Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Compositions of chemically modified insulin
    Patent number: 6890518
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: May 10, 2005
    Assignee: Nektar Therapeutics
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Pulmonary administration of chemically modified insulin
    Patent number: 6838076
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: January 4, 2005
    Assignee: Nektar Therapeutics
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Pulmonary administration of chemically modified insulin
    Publication number: 20030216542
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Application
    Filed: April 1, 2003
    Publication date: November 20, 2003
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche
  • Pulmonary administration of chemically modified insulin
    Publication number: 20030118510
    Abstract: The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
    Type: Application
    Filed: May 21, 2002
    Publication date: June 26, 2003
    Inventors: John S. Patton, Mei-Chang Kuo, J. Milton Harris, Chester Leach, Kimberly Perkins, Blaine Bueche